Impact of funding harm reduction programs for people who inject drugs in Mexico

被引:0
作者
Valenzuela-Lara, Marisol [1 ]
Ponce-Ramos, Marisol [2 ]
Ruiz-Herrera, Karen [2 ]
Lopez-Gonzalez, Agustin [3 ]
机构
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Ctr Nacl Prevenc & Control VIH & Sida, Direcc Atenc Integral, Mexico City, DF, Mexico
[3] Ctr Nacl Prevenc & Control VIH & Sida, Direcc Prevenc & Participac Social, Mexico City, DF, Mexico
关键词
People who inject drugs; harm reduction; HIV; HIV INCIDENCE; BORDER; TRANSMISSION; PREVENTION; RISK;
D O I
10.17711/SM.0185-3325.2019.021
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction. Despite evidence from harm reduction programs, there are limited data on their impact in Mexico. The Mexican National HIV Program has supported harm reduction programs implemented by community-based organizations both financially and technically. Objective. To obtain an estimate of HIV infections averted from 2015 to 2018. Method. A deterministic model was developed to estimate the number of infections, with harm reduction projects financed by CENSIDA and implemented by Community-Based Organizations, using data reported from the period 2015 to 2018. The benefit was obtained by estimating the costs of providing prevention programs and comparing the latter to the costs of providing care. Results. An analysis of 66,973 people included in harm reduction programs showed that an estimated 869 HIV infections were averted between 2015 and 2018. Potential savings obtained by providing these harm reduction services exceeded over $600,000 Mexican pesos for every infection averted. Discussion and conclusion. Harm reduction services play a key role in reducing the incidence of HIV in Mexico. Ensuring their financing is necessary since, combined with other services, they are a cost-effective tool for reducing the economic and public health burden of HIV/AIDS.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 38 条
  • [21] Magis-Rodríguez C, 2018, SALUD MENT, V41, P153, DOI [10.17711/sm.0185-3325.2018.023, 10.17711/SM.0185-3325.2018.023]
  • [22] The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
    Marzel, Alex
    Kusejko, Katharina
    Weber, Rainer
    Bruggmann, Philip
    Rauch, Andri
    Roth, Jan A.
    Bernasconi, Enos
    Calmy, Alexandra
    Cavassini, Matthias
    Hoffmann, Matthias
    Boni, Jurg
    Yerly, Sabine
    Klimkait, Thomas
    Perreau, Matthieu
    Gunthard, Huldrych F.
    Kouyos, Roger D.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (05):
  • [23] Mortality among people who inject drugs: a systematic review and meta-analysis
    Mathers, Bradley M.
    Degenhardt, Louisa
    Bucello, Chiara
    Lemon, James
    Wiessing, Lucas
    Hickman, Mathew
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2013, 91 (02) : 102 - 123
  • [24] Impact of length of injecting career on HIV incidence among people who inject drugs
    Montain, Jacqueline
    Ti, Lianping
    Hayashi, Kanna
    Nguyen, Paul
    Wood, Evan
    Kerr, Thomas
    [J]. ADDICTIVE BEHAVIORS, 2016, 58 : 90 - 94
  • [25] Barriers and missed opportunities to HIV testing among injection drug users in two Mexico-US border cities
    Moyer, Laura B.
    Brouwer, Kimberley C.
    Brodine, Stephanie K.
    Ramos, Rebeca
    Lozada, Remedios
    Cruz, Michelle Firestone
    Magis-Rodriguez, Carlos
    Strathdee, Steffanie A.
    [J]. DRUG AND ALCOHOL REVIEW, 2008, 27 (01) : 39 - 45
  • [26] Ni M. J., 2012, BMC PUBLIC HEALTH, V12, P12
  • [27] Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study
    Nosyk, Bohdan
    Zang, Xiao
    Min, Jeong E.
    Krebs, Emanuel
    Lima, Viviane D.
    Milloy, M-J
    Shoveller, Jean
    Barrios, Rolando
    Harrigan, P. Richard
    Kerr, Thomas
    Wood, Evan
    Montaner, Julio S. G.
    [J]. LANCET HIV, 2017, 4 (07): : E303 - E310
  • [28] Ospina-Escobar Angélica, 2016, Región y sociedad, V28, P45
  • [29] A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients
    Phelan, Maria
    Cook, Catherine
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [30] Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
    Platt, Lucy
    Easterbrook, Philippa
    Gower, Erin
    McDonald, Bethan
    Sabin, Keith
    McGowan, Catherine
    Yanny, Irini
    Razavi, Homie
    Vickerman, Peter
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (07) : 797 - 808